Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Perspective Therapeutics, Inc.AMEX: CATX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 21.5% from a year ago

Cash & equivalents stood at $53.97M at the end of Q1 FY2026, up 21.5% from a year earlier and up 76.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Cash & equivalents amounted to 13.1% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +21.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.97M+76.2% QoQ
Last fiscal yearDec 2025
$30.63M-50.3% YoY
Year agoMar 2025
$44.41M+21.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.5%——
1 year-50.3%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
30.63M USD
Year-over-year change
-50.3%
4-year CAGR
-15.6%

Cash & Equivalents vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's Mar 2026 cash & equivalents of $53.97M is the 3rd highest of the 5 companies compared; the peer median is $48.93M.
  • Its year-over-year change of +21.5% is the 3rd highest of 5, against a peer median of +109.7%.
  • Cash & equivalents amounts to 13.1% of total assets for CATX, versus a peer median of 34.3%.
CATX Competitors Peer median
Cash & Equivalents for CATX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVCRNovoCure LimitedMar 2026$97.32M -23.5%-3.6%12.4%
TLSITriSalus Life Sciences, Inc.Mar 2026$56.55M +335.0%+29.5%79.7%
CATXPerspective Therapeutics, Inc.Mar 2026$53.97M +21.5%+13.4%13.1%
DCTHDelcath Systems, Inc.Mar 2026$41.31M +223.4%+78.3%33.1%
SRTSSensus Healthcare, Inc.Mar 2026$18.33M -3.9%-4.7%35.6%
Peer median (excluding CATX) $48.93M+109.7%+13.0%34.3%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.35M20.99M9.24M61.58M30.63M
Short-term Investments022.76M0165.34M114.11M
Net Receivables1.65M1.36M1.18M116K6K
Inventory1.07M1.41M000
Other Current Assets535K6.69M5.35M4.13M3.65M
Total Current Assets63.6M53.22M16.84M231.16M148.39M
Property, Plant & Equipment (Net)2.62M2.06M6.32M59.54M78.1M
Goodwill0024.06M00
Intangible Assets107K86K50.35M50M40M
Long-term Investments0150K133K00
Tax Assets00000
Other Non-current Assets926K(2.3M)182K405K486K
Total Non-current Assets3.65M2.3M81.05M109.94M118.58M
Total Assets67.25M58.09M97.89M341.1M266.97M
Account Payables847K1.54M6.91M10.34M20.51M
Short-term Debt0049K52K623K
Tax Payables00000
Deferred Revenue0001.4M26.6M
Other Current Liabilities259K(406K)4.73M5.48M1.46M
Total Current Liabilities1.85M2.68M15.66M18.23M28.68M
Long-term Debt001.68M1.63M1.01M
Deferred Tax Liabilities004.59M2.5M1.7M
Deferred Revenue (Non-current)00026.6M0
Other Non-current Liabilities624K75K4.59M55K28.56M
Total Non-current Liabilities1.02M331K7.05M32.2M31.26M
Total Liabilities2.86M3.45M22.71M50.43M59.94M
Common Stock142K142K282K70K74K
Retained Earnings(95.17M)(105.93M)(152.44M)(231.72M)(334.84M)
Accumulated OCI000(51K)110K
Other Stockholders Equity0160.43M000
Minority Interest00000
Total Equity64.39M54.64M75.18M290.67M207.03M
Total Debt652K524K2.55M4.06M1.63M
Net Debt(59.7M)(20.99M)(6.69M)(57.52M)(29M)

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.